This page has been created with content from the Gilead‑organised symposium ‘Meeting Current and Evolving IFI Challenges – What Will You Do? Spotlight on 35 Years of AmBisome® liposomal (amphotericin B)’, which took place during the international conference Trends in Medical Mycology (TIMM), held between 19th–22nd September, 2025 in Bilbao, Spain. This meeting included promotional content and was intended for healthcare professionals only. The materials on this page are therefore considered promotional and intended solely for healthcare professionals practicing in the European Economic Area. This site is not intended for HCPs practicing in the United Kingdom.
This symposium celebrates 35 years of AmBisome liposomal (amphotericin B) in clinical practice, examining its enduring role in treating invasive fungal infections. Leading experts discuss real-world challenges, diagnostic gaps, and the future of antifungal therapy amid climate change and emerging resistance.
Main Presentations and Timestamps
Navigating IFI Complexity: Case Study Session (09:51)
- Complex ICU case studies including mixed fungal infections (Candida albicans and Aspergillus)
IFI Care in 2025: Bridging Diagnosis and Treatment Gaps (23:48)
- Diagnostic and treatment challenges in resource-limited settings, with focus on Greece
The Future of Antifungal Therapies: Navigating Emerging Needs (38:40)
- Impact of climate change, natural disasters, and armed conflicts on fungal disease epidemiology
- Current role of liposomal amphotericin B in breakthrough infections, mucormycosis, empiric and salvage treatment
- Future antifungal developments including GWT-1 inhibitors and co-infection management strategies
Speakers
Vanya Gant1
Dominic Wichmann2
Georgia Vrioni3
Martin Hönigl4
1. University College NHS Foundation Trust, London, UK
2. Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
3. Medical School, National & Kapodistrial University Of Athens, Greece
4. Medical University of Graz, Austria
The meeting and the materials included on this page comply with the Spanish‑approved label for AmBisome liposomal. Prescribing information may vary depending on local approval in each country. Therefore, before prescribing this product, always consult local materials such as the local prescribing information and/or the applicable SmPC.
For HCPs in Spain, prescribing information for AmBisome liposomal (amphotericin B) can be found here.
For English-speaking HCPs, prescribing information for AmBisome liposomal can be found here.
Adverse events should be reported to Gilead at [email protected] and/or through your national reporting system.
GFM-AMB-0074 | March 2026
